Exscientia plc (NASDAQ:EXAI) Stock Position Raised by Values First Advisors Inc.

Values First Advisors Inc. raised its position in shares of Exscientia plc (NASDAQ:EXAI) by 10.0% in the fourth quarter, Holdings Channel reports. The firm owned 55,958 shares of the company’s stock after buying an additional 5,090 shares during the period. Values First Advisors Inc.’s holdings in Exscientia were worth $359,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new stake in shares of Exscientia during the 3rd quarter worth about $344,000. Banque Pictet & Cie SA bought a new position in shares of Exscientia in the 3rd quarter valued at approximately $1,040,000. Platinum Investment Management Ltd. increased its position in Exscientia by 10.2% in the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock worth $19,866,000 after buying an additional 405,426 shares during the period. Federated Hermes Inc. bought a new position in Exscientia in the 3rd quarter worth approximately $362,000. Finally, Private Advisor Group LLC bought a new position in Exscientia in the 2nd quarter worth approximately $62,000. 41.58% of the stock is owned by hedge funds and other institutional investors.

Exscientia Price Performance

Shares of NASDAQ:EXAI traded down $0.06 during trading on Thursday, hitting $5.72. 504,352 shares of the stock were exchanged, compared to its average volume of 749,451. The company’s fifty day simple moving average is $6.20 and its 200-day simple moving average is $5.86. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22. Exscientia plc has a 1-year low of $4.17 and a 1-year high of $9.12.

Analyst Ratings Changes

Separately, Bank of America lowered Exscientia from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $11.00 to $9.00 in a report on Friday, January 5th.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.